Our latest insights

The Federal Court’s $5.8M ACL decision signals a new era for privacy, cybersecurity, and governance in Australia. It reinforces that privacy and cyber obligations start Day 1 of any acquisition, governance failures will be scrutinised, and accountability cannot be outsourced. Boards must ensure robust oversight, deep cyber due diligence, and forensic incident response. With OAIC escalating regulatory enforcement, organisations face heightened legal, financial, and reputational risks.

Built on world-class research and clinical trials, Australia’s biotech industry is increasingly shifting towards commercialisation, global expansion, and long-term growth.

In this episode of Beyond the Numbers with Grant Thornton, Management Consulting Partner, Richard Bycroft, and Director, Primo Danieletto, discuss automation in supply chains, triggers for reviewing an organisation’s current model and the ROI businesses can see from implementation.

Explore how life sciences firms can use sustainability to drive growth, resilience, and funding access.

The biotech industry faces significant challenges, including regulatory pressures, supply chain disruptions, rising costs and shifting investment landscapes.

Navigating the funding landscape can be tricky for biotech companies at all stages, from initial research and clinical trials to scaling up capabilities. Our recent roundtable discussions with over 90 Biotech CEOs, held in partnership with AusBiotech, shed light on the challenges and opportunities shaping the industry.

Biotechnology organisations often grapple with three key trends – where the next round of funding will come from, how to attract specialised talent to support vital innovation, and how to tackle manufacturing and scale up. They seek stability and certainty in funding to ensure projects are supported and reach their full potential. How can the upcoming Federal Budget announcement better support this sector?

Australia’s Biotechnology Sector Snapshot 2022, conducted by Ausbiotech and supported by Grant Thornton, has revealed an impressive 43% growth rate in the sector in the past two years.

New COVID-19 variants remain a risk for all world economies and this uncertainty has the potential to impact business confidence and investment decision-making. This will be weighing on the Australian Government as it fine-tunes the 2022-23 Federal Budget.

In consultation with patent attorneys from Griffith Hack, we have applied our expertise across patent law, R&D tax, corporate tax and industry specific knowledge to consider the challenges and opportunities for patent box here in Australia.

The 2021-2022 Federal Budget highlights new opportunities for the life sciences sector in Australia. Already a great place or research and development, it’s time we ramp up domestic commercialisation and manufacturing to better support and tap into international markets.

We’ve never been more aware of where our pharmaceuticals and medical products come from, or how long therapeutics take to go from research to product.